+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Transverse Myelitis Drug"

Transverse Myelitis - Pipeline Insight, 2025 - Product Thumbnail Image

Transverse Myelitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Transverse Myelitis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Transverse Myelitis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Transverse Myelitis is a rare neurological disorder that affects the spinal cord, causing inflammation and damage to the myelin sheath that covers the nerves. It is a type of Central Nervous System (CNS) disorder, and is typically treated with a combination of drugs and physical therapy. Common drugs used to treat Transverse Myelitis include corticosteroids, immunosuppressants, and antiviral medications. Corticosteroids are used to reduce inflammation and pain, while immunosuppressants are used to reduce the body's immune response. Antiviral medications are used to reduce the risk of infection. The Transverse Myelitis Drug market is a small but growing segment of the CNS Drugs market. It is a specialized market, with a focus on providing treatments for this rare disorder. Companies in this market include AbbVie, Biogen, Celgene, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more